| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.36 | 9e-13 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.33 | 6e-12 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.24 | 3e-11 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.26 | 2e-10 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.25 | 2e-09 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.24 | 2e-09 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.23 | 2e-08 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.23 | 2e-08 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.22 | 3e-08 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.22 | 4e-08 |